Cipla signs agreement with Novartis Pharma AG
Indian multinational pharmaceutical company Cipla entered into a perpetual licence agreement with Switzerland-based pharmaceutical company Novartis Pharma AG.
An Overview of the News
The agreement allows Cipla to manufacture and market diabetes drug Galvus and its combination brands from January 1, 2026.
Galvus is an oral anti-diabetic medicine that contains Vildagliptin as an active ingredient in it. It is used for the treatment of type 2 diabetes.
The perpetual licence agreement between Cipla and Novartis Pharma AG will enable Cipla to expand its product offerings in the diabetes segment.
About Novartis AG
It is a multinational pharmaceutical corporation.
The company is consistently ranked among the top five pharmaceutical companies globally.
Novartis is one of the world's largest pharmaceutical companies in terms of revenue.
In 2022, it was ranked as the fourth largest pharmaceutical company by revenue.
CEO - Vasanth Narasimhan
Subsidiaries - Sandoz, Novartis India Ltd.
Headquarters - Basel, Switzerland
Established - 29 February 1996
Founder - Johann Rudolf; Alexander Clavell
About Cipla Limited
It is an Indian multinational pharmaceutical company.
It primarily develops drugs to treat medical conditions such as heart disease, arthritis, diabetes, depression and respiratory diseases.
CEO - Umang Vohra
Founder - Khwaja Abdul Hameed
Headquarters - Mumbai
Subsidiaries – Cipla USA Inc., Cipla Health Ltd. etc.
Please Rate this article, so that we can improve the quality for you -